摘要
目的:观察安罗替尼维持治疗晚期卵巢癌的效果。方法:选取在我院治疗的60例晚期卵巢癌患者作为观察对象,按照随机数字表法将其分为观察组与对照组每组各30例。两组患者均采用TP(紫杉醇^(+)顺铂)方案化疗^(+)肿瘤细胞减灭术,对照组患者术后予以TP化疗2个疗程,之后定期复查,观察组患者术后予以TP化疗2个疗程后继续实施安罗替尼维持治疗。术后6个月,观察两组患者临床疗效,比较术后即刻、术后6个月两组患者血清相关指标、免疫功能及生活质量指标;记录两组患者术后3个月、6个月、12个月复发率情况。结果:观察组患者临床客观缓解率高于对照组,但差异无统计学意义(P>0.05)。术后6个月,两组患者血清肿瘤标志物CEA、CA125、CA199、VEGF水平及CTC阳性率均低于治疗前(P<0.05);观察组患者CEA、CA125、CA199、VEGF水平低于同期对照组(P<0.05),两组患者CTC阳性率比较差异无统计学意义(P<0.05);两组患者CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平明显高于治疗前且观察组高于对照组(P<0.05);两组患者CD8^(+)水平、QLQ⁃C30各维度评分低于治疗前,且观察组低于对照组(P<0.05)。随访期间两组患者均无化疗相关性死亡。观察组患者治疗后6个月、12个月总复发率均低于对照组(P<0.05)。结论:安罗替尼长期维持治疗晚期卵巢癌患者效果显著,可改善血清肿瘤标志物水平,增强免疫力,改善生活质量,能有效改善患者预后。
Objective:To investigate the efficacy of Anlotinib in maintenance therapy for advanced ovarian cancer.Methods:Included in this study were 60 patients with advanced ovarian cancer treated in our hospital,assigned to the study group and the control group according to random number table(n=30 each).The both groups of patients received chemotherapy based on paclitaxel and cisplatin(TP)regimen plus cytoreductive surgery.The control group received 2 cycles of TP chemotherapy after surgery,and then was followed up on a regular basis.The study group received 2 cycles of TP chemotherapy after surgery,and then was continued on maintenance therapy with Anlotinib.At 6 months post⁃surgery,the two groups of patients were measured for clinical efficacy.Related serum indices,immune function and quality of life were compared between groups immediately and at 6 months after surgery.The 3⁃,6⁃and 12⁃month recurrence rates after surgery in the two groups of patients were also recorded.Results:The objective clinical response rate was higher in the study group than that in the control group,but the difference was not statistically significant(P>0.05).At 6 months after surgery,the serum levels of tumor markers CEA,CA125,CA199,and VEGF,as well as the CTC positivity rate were lower than baseline in either group(P<0.05).At any given time point after surgery,the CEA,CA125,CA199 and VEGF levels were lower in the study group than those in the control group(P<0.05),but there was no significant difference in the CTC positivity rate between the two groups(P<0.05);the CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)levels were significantly higher than baseline in either group,and were higher in the study group than those in the control group(P<0.05);the CD8^(+)level and all domain scores of QLQ⁃C30 were lower than baseline in either group,and were lower in the study group than those in the control group(P<0.05).There were no chemotherapy⁃related deaths in either group during the follow⁃up.The overall recurrence rates at 6 and 12 months after su
作者
陆小玲
林华明
黄毅超
刘云军
黎昌国
黄逸生
麦大海
Lu Xiaoling;Lin Huaming;Huang Yichao;Liu Yunjun;Li Changguo;Huang Yisheng;Mai Dahai(Department of Oncology,Maoming People's Hospital,Maoming 525000,Guangdong,China)
出处
《广州医科大学学报》
2022年第4期65-70,共6页
Academic Journal of Guangzhou Medical University
基金
茂名市科技计划项目(190408101701597)。
关键词
卵巢癌
晚期
安罗替尼
疗效
Ovarian cancer
Advanced stage
Anlotinib
Efficacy
